IRB Raps Obese-trashing Prof

July 2nd, 2013 No comments »

The University of New Mexico has announced that its Institutional review board (IRB) has found that Professor Geoffrey Miller’s tweet telling Ph.D. applicants who were obese not to apply was not “research.” After the tweet went viral, Dr. Miller lamely defended it as part of a research project. It wasn’t.

The University said that it was proceeding with a “disciplinary process” against Dr. Miller.  An earlier communication from the University stated that Dr. Miller was not involved in any faculty searches at UNM. The University statement notes, “Whether Miller will continue at NYU or return to UNM is under discussion , but has not been determined.”

Interestingly, an article by Burmeister, Kiefner, Carels and Musher-Eizenman, “Weight Bias in Graduate School Admissions”, was published on-line June 20, 2013 in the journal, Obesity. While this is a small study, the researchers found no evidence of bias in letters of reference but there appears to be evidence of discrimination against applicants with obesity who had face-to-face interviews.


Arena to Get Second Shot at Approval

February 2nd, 2012 No comments »

Arena Pharmaceuticals Inc. (and its partner Esai Inc.) have announced that they have been informed by the Food and Drug Administration that an Advisory Committee meeting will be held in the second quarter on their weight loss drug candidate, lorcaserin.  Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin (NASDAQ:ARNA)  Arena is expected to produce information on efficacy and tumor development with their drug.

FDA Panel Approves Obesity Drug

December 8th, 2010 1 comment »

In a surprise vote, the FDA Advisory Committee voted to approve Orexigen Therapeutics obesity drug, Contrave. The vote was 13 to 7. This is the first obesity drug to win approval since 1999. The FDA will make the final decision but they usually follow the recommendations of their advisory committees. This opens the door for Vivus to obtain approval since their drug, Qnexa, had a superior efficacy finding. It probably also helps Arena’s lorcaserin to obtain a more favorable decision by the FDA.  See F.D.A. Panel Backs New Diet Pill –

LA Times cites Downey Obesity Report on FDA decision on Lorcaserin

October 24th, 2010 No comments »

October 23, 2010

The Los An gels Times has picked up our press release on the FDA decision on lorcaserin. FDA shoots down another weight-loss drug – See the Daily Downey.